ProCE Banner Activity

SWOG S1826: Phase III Trial of Nivolumab + AVD vs Brentuximab Vedotin + AVD for Newly Diagnosed Advanced cHL

Conference Coverage
Slideset

Results from the phase III SWOG S1826 trial demonstrated improved PFS and EFS with Nivo-AVD vs BV-AVD in newly diagnosed advanced classical Hodgkin lymphoma.

Released: June 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis